The U.S. biotech sector had already been through a brutal few years before the latest market crash. Robert F. Kennedy Jr.’s ...

Trump administration cuts across federal health agencies have sent shivers through a biotech industry already struggling ...

The current macro environment appears grim, given the uncertainty around the global trade war, along with ongoing ...

“While macro headlines/tweets continue to dictate stock performance, and we expect volatility to continue, we see biotech ...

With a "terrible" job market, empty labs, and mounting competition from China, the lifeblood of Kendall Square is under ...

they have a significant influence over the performance of the biotech sector as a whole. While investors may not be able to capitalize on the catalysts that "made or broke" these companies in Q1 ...

Given its strong financial performance and future growth potential, many analysts consider BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) one of the Most Promising Stocks in the biotech sector.

Omega Funds founder and managing director Otello Stampacchia isn’t afraid to tell it like he sees it.

Medicamen Biotech, operating in the Pharmaceuticals sector and classified as a Smallcap ... a low of ₹377 and a high of ₹630. In terms of performance, Medicamen Biotech has shown a return ...

Ajooni Biotech, operating in the Animal/Shrimp Feed sector and classified as a Smallcap ... of ₹4.95 and a high of ₹10.34. In terms of performance, Ajooni Biotech has shown a return of ...

Directives from President Donald Trump's administration to freeze grant funding from the National Institutes of Health may ...